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Abstract
Introduction
Given the overlapping modes of transmission of HIV, hepatitis B virus (HBV), and hepatitis
C virus (HCV), understanding the burden and relationship of these infections is critical for
an effective response. Representative data on these infections among males who inject
drugs (MWID), the key high-risk population for HIV in Vietnam, are currently lacking.
Methods
Data and stored specimens from Vietnam’s 2009-2010 Integrated Biologic and Behavioral
Survey, a cross-sectional study among high-risk populations, were used for this analysis.
Plasma samples were tested for HIV, HBV, and HCV using commercial assays. A question-
naire was administered to provide demographic, behavior, and service-uptake information.
Provincial-level analyses were conducted to profile MWID enrollees and to provide esti-
mates on the prevalence of HIV, HBV, and HCV infection.
Results
Among 3010 MWID sampled across 10 provinces, the median (range) HIV prevalence was
28.1% (1.0%-55.5%). Median prevalence for current HBV infection (HBsAg+) was 14.1%
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(11.7%-28.0%), for previous exposure to HBV (total anti-HBc+) was 71.4% (49.9%-83.1%),
and for current or past HCV infection (HCV Ag/Ab+) was 53.8% (10.9%-80.8%). In adjusted
analysis, HBsAg+ (aOR: 2.09, 1.01-4.34) and HCV Ag/Ab+ (aOR: 19.58, 13.07-29.33) sta-
tus were significantly associated with HIV infection; the association with total anti-HBc+ ap-
proached significance (aOR: 1.29, 0.99-1.68).
Conclusion
The prevalence and association between HIV, HBV, and HCV are high among MWID in
Vietnam. These findings indicate the need for integrated policies and practice that for the
surveillance, prevention, screening, and treatment of both HIV and viral hepatitis among
MWID in Vietnam.
Introduction
Similar modes of transmission of human immunodeficiency virus (HIV), hepatitis B virus (HBV)
and hepatitis C virus (HCV) can lead to an increased risk of HIV co-infection with HBV or HCV.
[1] Because HIV, HBV, and HCV can be efficiently transmitted via percutaneous exposure to
blood, people who inject drugs (PWID) are at especially high risk for infection and co-infection
with these viruses and for transmission to others through unsafe needle sharing or sex practices.[2]
Worldwide, of an estimated 240 million chronic HBV infections, 1.2 million (0.5%) occur
among people who inject drugs (PWID); of 170 million chronic HCV infections, 10 million
(5.9%) occur among PWID.[3] Chronic HBV and HCV infections are associated with increased
risk of cirrhosis and liver cancer and are responsible for more than 1 million deaths annually.
[3–6] Recent estimates also indicate that a significant amount of hepatitis B, hepatitis C, and HIV
burden, as determined by disease specific disability-adjusted life years, can be attributed to illegal
injection drug use.[7] The prevalence of HCV co-infection among HIV-infected PWID (HCV/
HIV) often exceed 50%.[1,2,8–11] Among people infected with HIV, co-infection with viral hepa-
titis adversely impacts morbidity and mortality and is becoming a leading cause of death among
co-infected PWID, even in the era of anti-retroviral therapy (ART) to treat HIV/AIDS.[12,13]
Up to 335,000 active males who inject drugs (MWID) live in Vietnam, making it one of the
six highest burden countries for injecting drug use worldwide.[14,15] Vietnams HIV epidemic
is concentrated among high-risk populations, specifically MWID, female sex workers (FSW),
and men who have sex with men (MSM).[15] Although these populations are not mutually ex-
clusive, MWID are reported to have the highest HIV burden with national prevalence estimat-
ed to be 14.4%MWID [15] The prevalence of current hepatitis B surface antigen (HBsAg), a
marker of active HBV infection and infectiousness, varies between 5.7% and 24.7% by popula-
tion. An estimated 8.4 million (~10% of the population) people in Vietnam are also chronically
infected with HBV.[16–18] The prevalence of antibody to HCV (anti-HCV), indicative of cur-
rent infection or previous exposure to hepatitis C, ranges between 0.38% and 1.7% in the gener-
al population in Vietnam but between 31–98.5% among MWID.[2,16]
These hepatitis data come from a variety of relatively small, localized surveys which lack the
ability to provide nationally or provincially representative data regarding the epidemiology and
frequency of HBV, HCV, or co-infection with HIV for Vietnam. Neither HBV nor HCV is a re-
quired reportable disease in Vietnam, and the country currently lacks routine hepatitis surveil-
lance systems.[16,17] Such data are needed about HBV and HCV infection among key
populations, such as MWID, for understanding the burden and profile of these key infections
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to organize appropriate resources for an effective response. The objectives of this analysis are
to profile behaviors relevant for HIV, HBV, and HCV acquisition and transmission; to present
representative estimates of HIV, HBV, HCV, and co-infection prevalence; and to identify risk
factors associated with HIV infection among MWID in Vietnam.
Methods
Study Population and Sampling
Data from the 2009 Integrated Behavioral and Biologic Survey (IBBS) were used for this study.
The 2009 IBBS was a cross-sectional survey of populations at increased risk for HIV in Vietnam
including male injecting drug users (MWIDs). The main objectives of IBBS were to assess a rep-
resentative sample of these key populations to determine HIV prevalence, associated behaviors
(e.g. condom use and needle-sharing behaviors), and exposure to HIV prevention and care ser-
vices. During September 2009–February 2010, MWID, defined as individuals self-reporting il-
licit injecting drug use at least one time in the previous 30 days aged18 years, were sampled
across 10 geographically diverse provinces in Vietnam that have received focused support in ad-
dressing HIV via the US President’s Emergency Plan for AIDS Relief (PEPFAR) program.
MWID were sampled in each province using either respondent driven sampling (RDS) (Hanoi,
Da Nang, Ho Chi Minh City (HCMC), Can Tho) or two-staged time-location sampling (TLS)
(Hai Phong, Quang Ninh, Nghe An, Yen Bai, Dong Nai, An Giang) based on formative provin-
cial mapping conducted by the study team as described in previous reports.[19]Inclusion of in-
jecting drug users in the Vietnam IBBS is limited to males given the assumption that the vast
majority of drug injectors are male and to allow comparability to previous surveys.
Following recruit eligibility screening and informed consent, trained staff conducted indi-
vidual interviews using a structured questionnaire. Blood samples were collected for HIV test-
ing and remnant samples were stored for potential testing in the future. Participants were
provided coupons and encouraged to return to obtain the HIV test results. All participants
were compensated between 50,000–100,000 VND ($2.50-$5.00) for their time and travel ex-
penses. A monetary compensation was also provided to RDS recruits who subsequently re-
cruited peers into the study at defined study locations.
Written, informed consent was obtained by reading a standardized study description and
consent form that was also provided to the study recruit for their review and signed agreement.
This consent process, which included the provision for future testing on stored specimens, was
approved by the below-described ethics review boards.
Ethical approval
The study protocol was reviewed and approved by the Vietnam National Institute of Hygiene
and Epidemiology (NIHE) Ethics Review Board and the Internal Review Board of the U.S. Cen-
ters for Disease Control and Prevention.
Laboratory analysis
HIV status was determined per national guidelines by screening for antibody to HIV using
Genscreen HIV Ultra HIV Ag/Ab (Bio-Rad) with confirmatory testing of those screened as
HIV-positive by Determine HIV ½ (Alere) and Murex HIV Ag/Ab Combination (DiaSorin).
An enrollee was classified as HIV-positive if all three tests were positive for HIV-infection. Ten
percent of HIV-negative samples and 5% of HIV-positive samples were randomly selected and
re-tested for quality assurance at the National Reference Laboratory at NIHE in Hanoi.[19]
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In August 2012, stored plasma from the IBBS study underwent serologic testing for
HBV and HCV infection at the Vietnam National Institute of Hygiene and Epidemiology
(NIHE) in Hanoi. Testing for HBsAg to determine current HBV infection was conducted
by using the Murex HBsAg Version 3; an optical density (OD) value >0.05 over the mean
negative control was interpreted as positive for HBsAg.[20] Specimens with indetermi-
nate, weakly positive or negative HBsAg results were also tested for total anti-HBc to de-
termine previous HBV infection by using the ETI-AB-COREK PLUS (DiaSorin). The
combination of results was used to classify the HBV infection status of each subject as:
‘current or active HBV infection’ (HBsAg+), ‘prior HBV infection’ (HBsAg-/total anti-
HBc+) or ‘susceptible to future HBV’ (HBsAg-/total anti-HBc-). Specimen quantity was
insufficient to test for antibody to hepatitis B surface antigen (anti-HBs). As such, a small
proportion of MWID classified as susceptible might have been immune from vaccination
although we anticipate this to be a small percentage given the low coverage rates of HBV
vaccination in this age group and population.[16]
Stored specimens also underwent combined testing for the presence of antibody to HCV or
HCV antigen (Murex HCV Ag/Ab Combination, DiaSorin). Specimens that tested indetermi-
nate or weakly positive were re-tested by the same methods. An OD value> 0.20 over the
mean negative controls was used as the cut-off definition for a positive result.[21] The subject’s
HCV infection status was classified as: ‘past or current HCV infection’ (HCV Ag/Ab+); ‘inde-
terminate/weakly positive’ (if repeat testing remained indeterminate/weakly positive); or ‘no
evidence of HCV infection’ (HCV Ag/Ab-).
Statistical Analysis
Simple frequencies and proportions were calculated for categorical variables by province;
and mean and medians were calculated for continuous variables. Prevalence estimates for
HIV, HBV, HCV, and co-infections among MWID with 95% confidence intervals (95% CI)
were calculated by province. Comparison of categorical data was done using the chi-square
test or Fisher’s exact test (if expected frequencies were less than 5). Any indicator missing
more than 5% of the total responses by province were reported in the respective output ta-
bles. For provinces sampled through RDS, analyses were done by using RDS Analyst (v0.1)
[22] with successive sampling estimator [23] applied apriori using mid-range MWID pro-
vincial population size estimates approved by the Vietnamese Ministry of Health. [24–25]
The remaining six provinces were analyzed using STATA (v.12.0).[26]
Median values and ranges were calculated for the total of provinces sampled. The Mann-
Whitney test was used to compare median values for different groups. Pairwise correlations,
and their significance levels using t-test probabilities, were calculated and reported to estimate
the provincial-level variation between HIV prevalence and HBV and HCV prevalence. For uni-
variate and multivariate risk factor analysis, unweighted odds ratios (OR) and 95% CI were cal-
culated by stratified (conditional) logistic regression with HIV status as the outcome variable
and stratified by ‘province’ to protect against any confounding (e.g. Simpson’s paradox) effect
that may appear in an unstratified analysis.[27] The rationale for combining data across all
provinces was to provide an increased sample size effectively increasing the power to detect key
estimates and associations resulting in more robust inferences. All independent variables indi-
cating an association with HIV status (p< = 0.20) in the univariate analysis were entered into a
multivariate conditional logistic regression model using backward step-wise selection and the
Wald test after estimation to identify the most parsimonious model. Collinearity was assessed
by examining the variance inflation factors (VIF) of the model; variables indicating strong col-
linearity (i.e. VIF>8.0) were removed from the final analysis.
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Results
Population characteristics and risk behaviors
Among the 10 provinces, [28] 3010 (3%) of an estimated 98,900 [24] MWID were sampled.
The median (range, by province) population was 2.03 (0.76–7.68) million (Table 1.1). The me-
dian estimated MWID population across the provinces sampled was 4,520 (1,197–46,213).
[24,28] The median age was 30.0 (21.5–35.5) years with the majority (>50%) of enrollees self-
reported never being married, but most (>90%) being sexually active.
Key risk behaviors by province for HIV among those sampled are presented in Table 1.2.
The median (range, by province) duration of drug use and injecting drug use was 8.2 (4.7–
11.3) and 5.9 (3.6–7.4) years respectively. In all provinces except Dong Nai, the majority of
enrollees reported injecting drugs one or more times per day with a median of 39.1%
(28.1%-70.2%) of MWID reported having ever shared needles or syringes with others during
injection drug use. Relatively few (3.0% [0.3%-5.9%]) MWID reported sharing needles ‘al-
ways or most of the time’ when they inject drugs, although 56.1% (29.8%-71.7%) of enrollees
gave no response for this indicator. The vast majority (97.0% [83.3%-98.4%]) of all MWID
sampled did report receiving free clean needles and syringes sometime in the past 12 months.
An estimated 32.6% (15.0%-47.9%) of MWID reported having sexual relations with a female
sex worker in the previous 12 months, and, of those who had, the majority (79.6% [49.1%-
91.1%]) reported having used a condom during the last such encounter. A median of 38%
(25.3–68.4%) of MWID reported previously testing for HIV.
HIV, HBV, and HCV prevalence
HIV prevalence among MWID varied widely by province (Fig. 1); the median HIV preva-
lence was 28.2% (1–55.5%) (Table 2). Across all 10 provinces, 14.1% (11.7%-28.0%) of
MWID demonstrated active HBV infection (i.e., HBsAg+) and among those who were
HBsAg-, 71.4% (49.9%-83.1%) had evidence of previous HBV infection (61.3% of the
overall population sampled). Across provinces, median prevalence of past or current HCV
infection among MWID overall was 53.8% (10.9%-87.4%). See the S1 Table for individual
provincial-level data related to HIV, HBV, and HCV.
HIV-positive participants were more likely than HIV-negative participants to have evi-
dence of previous HBV infection (81.2% vs. 64.7%, p-value<0.005); active HBV infection
status did not differ significantly between HIV-positive and HIV-negative MWID (15.7%
vs. 16.4%, p-value>0.05). Thus, a median (range) of 4.6% (0.9%-13.4%) of all MWID sam-
pled were HIV-infected and currently co-infected with HBV, and 19.7% (0.1%-39.0%)
were HIV-positive and evidenced past HBV infection (Table 2). In all provinces except
Hanoi and Da Nang, past or current HCV infection was higher among HIV-positive than
HIV-negative respondents (overall: 95.8% vs. 52.2%, p-value<0.0005) (Table 2). Overall,
across all provinces, a median of 26.8% (14.1%-55.2%) of sampled MWID tested positive
for both past or current HCV infection and HIV, with markedly high prevalence (> =
50%) among MWID in Hai Phong and Quang Ninh. In contrast, no participants in Da
Nang province, with its relatively low HIV prevalence (1% [0%-2.4%]), tested positive for
both HIV and past or current HCV infection, potentially indicating evidence of low HCV/
HIV co-infection prevalence there (See supplemental table).
At the provincial level, HIV prevalence was significantly correlated with past HBV infection
prevalence (r = 0.73, p-value = 0.02) and past or current HCV infection prevalence (r = 0.87,
p-value = 0.0001) and weakly correlated with active HBV infection prevalence (r = 0.14,
p-value = 0.70) (Fig. 1).
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Table 2. HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), and co-infection prevalence.
Sero-marker Median (Range) across sampled
provinces% (95% CI)
HIV 28.1 (1–55.5)
HBsAg+ 14.1 (11.7–28)
HIV+ 15.7 (9.6–66.7)
HIV- 16.4 (10.3–22.8)
HBsAg-/total anti-HBc+ 71.4 (49.9–83.1)
HIV+ 81.2 (31.7–100)*
HIV- 64.7 (49–78.1) *
HCV Ag/Ab+ 53.8 (10.9–87.4)
HIV+ 95.8 (35.5–99.4) *
HIV- 52.2 (10.9–80.8) *
HBV, HCV and HIV prevalence (among all enrollees with
a recorded result)
HBsAg+/HIV+ % (95% CI) 4.6 (0.9–13.4)
anti-HBc+/HIV+ % (95% CI) 19.7 (0.1–39)
HCV Ag/Ab+/HIV+ % (95% CI) 26.3 (14.1–55.2)
HBsAg+/HCV Ag/Ab+/HIV+ % (95% CI) 1.2 (0.3–2.9)
* indicate p-value <0.05
doi:10.1371/journal.pone.0118304.t002
Fig 1. Provincial level correlation* of HIV to HBsAg, total anti-HBc, and HCV in the 2009 IBBS.
doi:10.1371/journal.pone.0118304.g001
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Factors associated with HIV status
Bivariate analysis (Table 3a) at the individual level also identified associations between HIV in-
fection and past HBV infection (OR: 2.40, 1.93–2.99) and past or current HCV infection (OR:
29.84, 20.64–43.16). The association between HIV and active HBV infection (OR: 1.19, 0.94–
1.49) was statistically not-significant. Several other factors were also associated with HIV sta-
tus, including: increased duration and frequency of injecting drug use and needle sharing, in-
jecting heroin exclusively compared to also injecting other drugs, increased MWID network
size, ever being tested for HIV infection and ever being detained in a drug rehabilitation center.
In adjusted analysis, which controlled for controlled for age category, duration of injecting
drug use, type of drug use, current HBV infection, previous HBV infection status, and past or
current HCV infection status, HIV infection was positively associated with MWID aged 24–30
years (relative to those aged 18–24 years; aOR: 1.85, 1.30–2.62), those injecting drugs longer
than 3 years (relative to those injecting less than 3 years; aOR (3–5 years): 1.74, 1.04–2.93, aOR
(> = 5years): 3.01, 1.87–4.89), and negatively associated with MWID who do not use heroin
(aOR: 0.24, 0.08–0.68) (Table 3b). Both HBsAg+ (aOR: 2.09, 1.01–4.34) and HCV Ag/Ab+
(aOR: 19.58, 13.07–29.33) were also significantly associated with HIV infection in the adjusted
analysis. While not statistically significant at the defined level, total anti-HBc+ among those
HBsAg-(aOR: 1.29, 0.99–1.68) appears to indicate an association with HIV infection. No col-
linearity was identified among the variables included in the final adjusted analysis.
Conclusion
This study indicates that the prevalence of HIV, HBV, HCV and their co-infection among
MWID in Vietnam are high in the majority of provinces sampled. HIV infection is associated
with previous HBV infection and with current or past HCV infection (HCV Ag/Ab+) in both
provincial and individual-level analyses. Injection of heroin, as opposed to other drugs, is asso-
ciated with HIV infection as is an intermediate age range (24–30 years of age) and longer dura-
tion of injection drug use, in-line with expectations.
Our findings support previous, but localized studies, which indicate that the burden of HIV,
HBV, and HCV infection is high among MWID in Vietnam.[2,16,17,29,30] While the point
prevalence of HIV at the provincial level appears to be higher than what is reported through
the Vietnam annual sentinel surveillance, the wide variation by province is similar for this
study and the sentinel surveillance data. This supports the geographically heterogeneous char-
acterization [15] of the HIV epidemic among MWID that may be due to a variety of factors in
each province including: key population sizes (e.g. MWID), availability of HIV/AIDS preven-
tion and care services (e.g. coverage of needles and syringe exchange programs, HIV counseling
and testing, and HIV/AIDS treatment), duration of risk (e.g. duration of injecting use), and
risk behaviors (e.g. types of drugs used, frequency of needle sharing among MWID), and drug
trafficking routes that often enter Vietnam from the north and north-west potentially leading
to increasing injecting drug use and associated HIV. This study provides a more geographically
and population-representative profile of these associations and correlations than had previous-
ly been available for MWID in Vietnam and provides both provincial-specific estimations of
HIV, HCV, and HBV burden and relationship that may also be considered for the national
context. Specifically, it provides previously unavailable estimation about the significant associa-
tion between HIV infection and current, active HBV infection (HBsAg+) and indication of an
association between HIV infection with previous infection with HBV (total anti-HBc+) when
controlling for other key factors. The absolute burden of HCV and its substantial association
with HIV infection further indicates a clear clinical and public health issue for MWID in
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Table 3. Crude and Adjusted Associations between HIV prevalence (outcome) and select factors
among MWID in Vietnam.
Independent
predictor (n,
%)
Table 3a: Crude Associations between HIV
prevalence and select factors
Table 3b: Adjusted Associations
between HIV prevalence and
select factors
Observations Odds
Ratio
(OR)
95%
Conﬁdence
Interval
p-value Adjusted
Odds
Ratio
(aOR)
95%
Conﬁdence
Interval
p-value
Age Category 2986 (% HIV
+)
18–24 881 (11.80) 1 - - 1
24–30 706 (41.08) 3.85 2.94, 5.03 <0.0005 1.85 1.30, 2.62 0.001
> = 30 1399 (38.03) 3.09 2.39, 3.98 <0.0005 1.31 0.93, 1.83 0.12
Ethnicity
Category
3007
Kinh 2909 (30.90) 1 - -
Other 98 (32.65) 0.87 0.55, 1.37 0.55
Education 2982
Illiterate 120 (19.17) 1 - -
Primary 445 (31.91) 1.82 1.09, 3.04 0.02
Secondary 1198 (32.30) 1.85 1.13, 3.02 0.01
High School 1087 (31.37) 1.46 0.88, 2.42 0.14
College,
University
132 (22.73) 1.34 0.72, 2.56 0.38
Marital Status 3005
Never Married 1800 (28.56) 1 - -
Currently
Married
789 (32.07) 1.07 0.88, 1.31 0.48
Divorced 286 (36.01) 1.15 0.87, 1.53 0.32
Separated 110 (43.64) 1.36 0.90, 2.05 0.15
Widowed 12 (60.00) 2.79 1.09, 7.15 0.03
Unemployed 3000
Yes 118 (44.92) 1 - -
No 2882 (30.46) 0.55 0.36, 0.83 0.004
Duration of
drug use
2952
< 1 year 202 (4.46) 1 - -
1–3 years 535 (9.35) 2.3 1.10, 4.82 0.03
3–5 years 383 (21.15) 5.17 2.50, 10.67 <0.0005
> = 5 years 1832 (42.41) 11.66 5.87, 23.18 <0.0005
Duration of
injecting drug
use (IDU)
2952
< 1 year 391 (7.93) 1 - - 1
1–3 years 671 (13.71) 1.77 1.14, 2.74 0.01 1.13 0.66, 1.94 0.46
3–5 years 458 (28.38) 3.59 2.33, 5.54 <0.0005 1.74 1.04, 2.93 0.04
> = 5 years 1415 (46.64) 7.53 5.08, 11.19 <0.0005 3.03 1.87, 4.89 <0.0005
Frequency of
IDU (in the
past month)
3007
(Continued)
HIV and Hepatitis among Vietnamese Male Injecting Drug Users
PLOS ONE | DOI:10.1371/journal.pone.0118304 February 18, 2015 11 / 17
Table 3. (Continued)
Independent
predictor (n,
%)
Table 3a: Crude Associations between HIV
prevalence and select factors
Table 3b: Adjusted Associations
between HIV prevalence and
select factors
Observations Odds
Ratio
(OR)
95%
Conﬁdence
Interval
p-value Adjusted
Odds
Ratio
(aOR)
95%
Conﬁdence
Interval
p-value
> = 4 times
per day
95 (28.42) 1 - -
2–3 times per
day
1471 (33.99) 1.53 0.94, 2.47 0.09
1 time per day 832 (26.20) 1.46 0.88, 2.44 0.15
<1 time per
day
592 (30.07) 2.17 1.28, 3.69 0.004
Don’t know/no
response
17 (47.06) 4.07 1.36, 12.11 0.01
Type of
drugs
injected in
the past
month
3009
Heroin
exclusively
2751 (32.35) 1 - - 1 - -
Heroin as well
as other drugs
175 (18.29) 1 0.64, 1.57 0.99 1.36 0.76, 2.43 0.31
Drugs other
than heroin
83 (12.05) 0.41 0.20, 0.81 0.01 0.24 0.08, 0.68 0.01
Frequency of
needle/
syringe
sharing
3007
Never 1627 (22.56) 1 - -
Ever shared in
the past year
977 (46.98) 2.87 2.38, 3.47 <0.0005
Ever shared in
the past
month
403 (26.05) 1.47 1.13, 1.93 0.01
MWID
network size
2955
<5 574 (23.87) 1 - -
5-<15 1318 (29.59) 1.18 0.93, 1.51 0.17
>15 907 (35.75) 1.47 1.15, 1.88 0.002
Sexually
active
3009
Yes 2711 (31.02) 1 - -
No 298 (30.54) 0.98 0.74, 1.30 0.90
Sex with
female sex
worker in
past 12
months
1947
No 1216 (29.19) 1 - -
Yes 731 (41.48) 0.81 0.64, 1.02 0.07
(Continued)
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Vietnam, particularly given the relative efficiency of HCV transmission via blood from needle
sharing among MWID.[31]MWID
The association between HIV infection and infection with HBV and HCV when adjusted
for demographics, behavior, and service uptake provide evidence that MWID in Vietnam
should be counseled on risks and risk reduction for HIV, HBV, and HCV (e.g. cessation, reduc-
tion of injection drug use, non-sharing of needles and syringes, consistent condom use). Ser-
vices such as opioid substitution therapy should be provided as early as possible in their
injecting lifetime to prevent acquiring and transmitting HIV, HBV, and HCV. Intervening
early (e.g. within 1 year of injecting drug use initiation and at an earlier age) with MWIDs may
have a substantially positive impact not only on HIV infection but also on associated HBV and
HCV infection or HCV re-infection. This may be relevant especially among heroin injectors
who make up an estimated 85% of drug users in Vietnam.[32]
Table 3. (Continued)
Independent
predictor (n,
%)
Table 3a: Crude Associations between HIV
prevalence and select factors
Table 3b: Adjusted Associations
between HIV prevalence and
select factors
Observations Odds
Ratio
(OR)
95%
Conﬁdence
Interval
p-value Adjusted
Odds
Ratio
(aOR)
95%
Conﬁdence
Interval
p-value
Ever tested
for HIV
2830
Yes 1161 1 - -
No 1669 0.55 0.46, 0.66 <0.0005
Received free
needles and
syringes in
past 12
months
1361
Yes 1297 (35.0) 1 - -
No 64 (32.81) 0.75 0.43, 1.32 0.32
Ever been in
a drug
rehabilitation
center?
3005
No 1999 (25.66) 1 - -
Yes 999 (41.54) 2.21 1.86, 2.64 <0.0005
Don’t know/no
response
7 (42.86) 2.39 0.53, 10.79 0.26
HBsAg+ 3009
No 2554 (30.50) 1 - - 1
Yes 455 (33.63) 1.19 0.94, 1.49 0.14 2.09 1.01, 4.34 0.05
total anti-HBc
+
2585
No 785 (17.45) 1 - - 1
Yes 1800 (36.56) 2.40 1.93, 2.99 <0.0005 1.29 0.99, 1.68 0.06
HCV Ag/Ab+ 3004
No 1,224 (40.8) 1 - - 1 - -
Yes 1780 (59.3) 29.84 20.64, 43.16 <0.0005 19.58 19.46,
132.84
<0.0005
doi:10.1371/journal.pone.0118304.t003
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Given that Vietnam’s estimated 335,000 MWID represent the most-at-risk-population for
acquiring and transmitting HIV and HBV and HCV, accurate and timely data are critical for
understanding the epidemiologic profile as well as designing and expanding appropriate inter-
vention and care programs for those at risk for such HBV/HIV and HCV/HIV. We believe that
this study provides an example to the Government of Vietnam (GVN) and other stakeholders
of more integrated, and potentially more efficient, disease surveillance, particularly among
populations such as MWID that are at increased risk for HIV and viral hepatitis.
HIV/AIDS prevention, care, and treatment services in Vietnam have expanded considerably
over the past decade, primarily through initiatives supported by PEFPAR) the Global Fund
Against HIV/AIDS, TB, and Malaria, as well as projects supported by the World Bank and the
UK Department for International Development. These initiatives have supported the GVN to
expand HIV treatment, medical methadone therapy (MMT), and various harm-reduction ef-
forts for MWID. The Vietnam government has set an ambitious goal to initiate 80,000 injecting
drug users on MMT by 2015 although significant barriers exist towards achieving that includ-
ing conflicting policies for the treatment or incarceration of PWID as well as decreasing finan-
cial support from domestic and international sources.[32] There were 22,000 PWIDs that had
initiated MMT as of late 2014.[33] Despite progress in HIV/AIDS prevention and control in
Vietnam, a limited number of programs and strategies focus on other key co-infections, such
as HBV or HCV.[34,35] The potential impact of integrated prevention interventions are fur-
ther supported by data from this study indicating that, in addition to its association with HIV
infection, increased duration of injecting drug use (i.e.> = 1 year) among enrolled MWID in-
jecting heroin is significantly associated with prior HBV infection (data not shown).
Treatment programs for HIV and HBV and HCV should be fully integrated and evaluated.
In February 2011, revision to the Vietnam ART guidelines recommended the use of tenofovir
(TDF) and lamivudine (3TC) containing regimens that would provide an additional antiviral
effect against HBV and also potentially improve HCV-related outcomes.[36,37] Such control
efforts are especially critical given a recent study from Vietnam that reports a high (15.4%) of
hepatitis D virus among those with current HBV infection which may have a negative impact
on HBV-related outcomes.[38] International guidelines also indicate the need for hepatitis B
vaccination, screening and the appropriate care of HBV and HCV as a key component of com-
prehensive HIV prevention, care, and treatment among MWID [5,39–41] This will be particu-
larly important as increased access to HIV treatment in Vietnam will likely contribute to
longer life-spans of HIV-infected people, resulting in a positive impact on the chronic morbidi-
ty and mortality of HBV and HCV-associated liver disease.[10,42,43]
There are several limitations and potential biases to consider with these findings. We are un-
able to make inferences about the temporal relationships among injecting drug use, infection
with HIV, and infection with HBV or HCV due to the cross-sectional design of the study and
because we did not have sufficient serum to test for markers of acute HBV or HCV infection.
However if one assumes that injecting drug use is a significant mode of infection for HIV,
HBV, and HCV among MWID, then HCV and HBV infection likely precede HIV infection
due to their ease of transmission relative to HIV. [39,44,45] Also because of insufficient serum,
we did not test for anti-HBs, so we were unable to identify occult HBV or to define the frequen-
cy of immunity to HBV obtained through vaccination. However, given the low coverage rates
of HBV vaccination in this age group and population [16], few participants in this study are
likely to have been previously vaccinated. Factors associated with viral infection were analyzed
with all provinces combined under the assumption that associations were similar across prov-
inces and to increase power of the study to provide valid inferences that could more readily be
translated into policy and practice. In addition, sexual orientation was not assessed in this sur-
vey which limits any analysis of male-male sex behavior as a risk factor. Such data should be
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considered for future research. Finally, our sampling frame, while larger than any previous sur-
vey, was not designed to be nationally representative which might limit the generalizability of
these findings to all provinces in Vietnam.
In conclusion this study provides important information on the profile and burden of HIV,
HBV, HCV, and their associated co-infection among MWID in Vietnam. Such estimates are
important for advocating for funding and political commitment and for developing, and moni-
toring comprehensive, effective harm-reduction and universal vaccination programs that si-
multaneously address viral hepatitis and HIV/AIDS. Our results support the conclusion that
adequately responding to HIV and viral hepatitis among MWID requires integrated policies,
surveillance, and prevention, screening, and treatment programs.
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